Propranolol 0.2% Eye Micro-Drops for Retinopathy of Prematurity: A Prospective Phase IIB Study

• Main Authors: Luca Filippi (Author), Giacomo Cavallaro (Author), Elettra Berti (Author), Letizia Padrini (Author), Gabriella Araimo (Author), Giulia Regiroli (Author), Genny Raffaeli (Author), Valentina Bozzetti (Author), Paolo Tagliabue (Author), Barbara Tomasini (Author), Annalisa Mori (Author), Giuseppe Buonocore (Author), Massimo Agosti (Author), Angela Bossi (Author), Gaetano Chirico (Author), Salvatore Aversa (Author), Pina Fortunato (Author), Silvia Osnaghi (Author), Barbara Cavallotti (Author), Martina Suzani (Author), Maurizio Vanni (Author), Giulia Borsari (Author), Simone Donati (Author), Giuseppe Nascimbeni (Author), Daniel Nardo (Author), Stefano Piermarocchi (Author), Giancarlo la Marca (Author), Giulia Forni (Author), Silvano Milani (Author), Ivan Cortinovis (Author), Maura Calvani (Author), Paola Bagnoli (Author), Massimo Dal Monte (Author), Anna Maria Calvani (Author), Alessandra Pugi (Author), Eduardo Villamor (Author), Gianpaolo Donzelli (Author), Fabio Mosca (Author)
• Format: Book
• Published: Frontiers Media S.A., 2019-05-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background: Oral propranolol reduces retinopathy of prematurity (ROP) progression, although not safely. Propranolol 0.1% eye micro-drops administered to newborns with stage 2 ROP are well-tolerated, but not sufficiently effective.Methods: A multi-center open-label trial was conducted to assess the s...